Bio Medica Laboratories Reports H1 FY27 Financial Results
Bio Medica Laboratories Ltd · Financial Result · 13 Nov 2026, 11:05 pm
Bio Medica Laboratories Reports H1 FY27 Financial Results Bio Medica Laboratories reported consolidated revenue from operations of ₹2,160.78 lakhs and total income of ₹2,219.16 lakhs for the half-year ended 30th Sep'26. Consolidated profit before tax reached ₹478.81 lakhs, while profit after tax after minority interest stood at ₹312.54 lakhs. On a standalone basis, revenue from operations came in at ₹1,668.64 lakhs with a net profit of ₹283.81 lakhs. Cash and cash equivalents surged to ₹2,510.34 lakhs consolidated, aided by ₹3,901.75 lakhs in securities premium received during the period.
Original exchange filing (PDF)
More announcements from Bio Medica Laboratories Ltd
- Monitoring Agency Report for the half year ended 30th September, 2026, issued by CARE Ratings Limited ( Monitoring Agency ), in respect of the utilization of proceeds raised through Initial Public Offer by the Company · 14 Nov 2026
- Bio Medica Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 13 Nov 2026
- Bio Medica Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 13 Nov 2026
- Bio Medica Laboratories Limited has informed the Exchange about Board Meeting to be held on 13-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . · 13 Nov 2026
- BMLL : 13-Nov-2026 : The Company has informed the Exchange that a Board meeting to be held on November 05, 2026 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on November 13, 2026, To consider and approve the financial results for the period ended September 30, 2026 · 13 Nov 2026
- Bio Medica Laboratories Limited has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . · 05 Nov 2026
- To consider and approve the financial results for the period ended September 30, 2026 · 05 Nov 2026
- Non-Applicability of Corporate Governance Report for the 2nd Quarter Ended on 30th September, 2026. · 26 Oct 2026
